Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with lenvatinib within its marketing authorisation for untreated PD-L1 positive metastatic non- small- cell lung cancer.
As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer. For information, the company have announced that they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
 
Status Suspended
Decision Selected
Process STA 2018
ID number 3809

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
22 October 2021 Suspended. As you will be aware the Department for Health and Social Care has asked NICE to carry out an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer. For information, the company have announced that they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
12 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
04 February 2021 - 04 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
03 March 2020 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual